Analysts puzzle over plan to sell a Vioxx-like drug
Furor over the Merck product spurred push to tighten FDA rules
Some analysts are scratching their heads at the move Merck & Co. is planning : The drug maker wants to sell a new painkiller that is just like Vioxx , the blockbuster drug it pulled from the market in 2004 because the treatment doubled heart risks. (Full article: 860 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
